Probi gains new industrial shareholder in Symrise of Germany

The Probi probiotic company, which is listed on the Nasdaq OMX Nordic Exchange
Stockholm, has gained a new industrial shareholder in the German company
Symrise. Symrise has acquired a total of 1,102,301 shares, corresponding to 11.8
% of the capital and 12.1 % of the voting rights in the company, making it
Probi’s largest shareholder. This information has been published in a notice
disclosing a significant change in ownership.
Symrise is a leading global supplier of fragrances, flavourings, raw materials
and functional ingredients. The company’s customers include leading
manufacturers in the beauty, food and pharmaceutical industries and its products
are used in a number of everyday items, including perfumes, bodycare products,
textiles, healthcare products, consumer healthcare products, beverages, ready
-made food, sweets and dairy products.

The company has two business areas: Flavor and Nutrition, which includes an
extensive consumer healthcare division, and Scent and Care. The value chain of
both business areas includes research, purchasing, product development,
marketing, sales and customised solutions. The company’s focus is on developing
innovative solutions and products for global customers in new markets. With a
market share of approximately 10 %, Symrise is the world’s fourth largest
supplier of fragrances and flavourings.

Symrise has nearly 5,500 employees and is active in 35 countries, with sales
operations in 160 countries. The company’s sales in 2011 totalled approximately
EUR 1.6 billion. Symrise has been listed on the Frankfurt Stock Exchange since
2006 under the ticker SY1.

“We are pleased to welcome Symrise as a new shareholder in Probi. Symrise has
significant industrial expertise and a global network. There is currently no
industrial collaboration between Probi and Symrise, but we intend to investigate
the benefits of such a partnership,” says Michael Oredsson, CEO of Probi.

This information is such that Probi AB is required to disclose in accordance
with the Swedish Securities Market Act and/or the Financial Instruments Trading
Act.

FOR FURTHER INFORMATION, CONTACT:

Per Lundin, Chairman of the Board, Probi, mobile: +46 705 74 11 71, e-mail:
per.lundin@transit.se
Michael Oredsson, CEO, Probi, phone: +46 46 286 89 23, mobile: +46 707 18 89 30,
e-mail: michael.oredsson@probi.se

ABOUT PROBI

Probi is a leading player in probiotic research and the development of efficient
and well-documented probiotics. Its research areas include: gastrointestinal
tracts, immune system, metabolic syndrome and stress and recovery. Probi’s
customers are leading companies in the functional foods and consumer healthcare
business areas. Income for 2011 totalled MSEK 95.0. Probi’s share is listed on
the Nasdaq OMX Stockholm, Small Cap. Probi has approximately 5,000 shareholders.
For more information, please visit www.probi.se.

ABOUT SYMRISE

For further information about Symrise, please visit www.symrise.com.